Results 211 to 220 of about 10,250,216 (364)
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande +11 more
wiley +1 more source
Integrating clinical genetics in cardiology: Current practices and recommendations for education. [PDF]
Scherr CL +8 more
europepmc +1 more source
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard +12 more
wiley +1 more source
Leveraging PCORnet® to Advance Clinical Genetics and the Genomic Learning Health System. [PDF]
Rothman RL +8 more
europepmc +1 more source
Meeting abstracts from the Annual Conference "Clinical Genetics of Cancer 2022". [PDF]
europepmc +1 more source
Clinical genetics evaluation and testing of connective tissue disorders: a cross-sectional study. [PDF]
Veatch OJ +3 more
europepmc +1 more source
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard +5 more
wiley +1 more source
From tradition to transformation: evolving models of care in clinical genetics. [PDF]
Curd H, Gorrie A, Fennell AP.
europepmc +1 more source
Clinical Genetics of Inherited Arrhythmogenic Disease in the Pediatric Population. [PDF]
Martínez-Barrios E +9 more
europepmc +1 more source

